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A B S T R A C T
CTCF is an evolutionarily conserved and ubiquitously expressed architectural protein regulating a plethora of cellular functions via diﬀerent molecular mechanisms.
CTCF can undergo a number of post-translational modiﬁcations which change its properties and functions. One such modiﬁcations linked to cancer is poly(ADP-
ribosyl)ation (PARylation). The highly PARylated CTCF form has an apparent molecular mass of 180 kDa (referred to as CTCF180), which can be distinguished from
hypo- and non-PARylated CTCF with the apparent molecular mass of 130 kDa (referred to as CTCF130). The existing data accumulated so far have been mainly
related to CTCF130. However, the properties of CTCF180 are not well understood despite its abundance in a number of primary tissues. In this study we performed
ChIP-seq and RNA-seq analyses in human breast cells 226LDM, which display predominantly CTCF130 when proliferating, but CTCF180 upon cell cycle arrest. We
observed that in the arrested cells the majority of sites lost CTCF, whereas fewer sites gained CTCF or remain bound (i.e. common sites). The classical CTCF binding
motif was found in the lost and common, but not in the gained sites. The changes in CTCF occupancies in the lost and common sites were associated with increased
chromatin densities and altered expression from the neighboring genes. Based on these results we propose a model integrating the CTCF130/180 transition with
CTCF-DNA binding and gene expression changes. This study also issues an important cautionary note concerning the design and interpretation of any experiments
using cells and tissues where CTCF180 may be present.
1. Introduction
The CCCTC-binding factor (CTCF) is an evolutionarily conserved
and ubiquitous chromatin protein that regulates 3D genome archi-
tecture and participates in multiple cellular functions including tran-
scriptional activation, silencing, insulation, mediation of long range
chromatin interactions and others [1–8]. Signiﬁcant eﬀorts are cur-
rently devoted to the investigation of molecular mechanisms of CTCF
functioning in normal cells and disease using new generations of high-
throughput sequencing [9–11]. This question is particularly important
because CTCF binds to numerous sites of unclear function in the human
genome, and some of these binding sites diﬀer between diﬀerent cells of
the same organism [6,9,10,12,13].
Post-translational modiﬁcations of chromatin proteins (histones,
transcription factors and others) are known to play an important role in
diﬀerential protein binding in chromatin. Poly(ADP-ribosyl)ation
(PARylation) is one of such modiﬁcations performed by poly(ADP-
ribose) polymerases (PARPs) [14, 15]. Phylogenetically ancient PAR-
ylation is involved in the regulation of numerous cellular functions,
such as DNA repair, replication, transcription, translation, telomere
maintenance and chromatin remodeling [16–19]. A growing body of
evidence demonstrates the link between CTCF PARylation and its bio-
logical functions. For example, the insulator and transcription factor
functions of CTCF have been found to be regulated by PARylation [20,
21]. The eﬀect of CTCF PARylation is important in DNA damage re-
sponse [22]. A number of studies reported direct interaction between
CTCF and poly(ADP-ribose) polymerase 1 (PARP1), as well as their co-
localization in chromatin [23–25]. Furthermore, PARP1 and CTCF have
been found to regulate the transition between active and repressed
chromatin at the lamina [26]. A highly PARylated form of CTCF is re-
presented by a protein with an apparent molecular mass 180 kDa
(CTCF180), whereas the commonly observed CTCF130, is hypo- or non-
PARylated. CTCF130 has been found in many immortalized cell lines
and cancer tissues [23, 27–29]. Interestingly, only CTCF180 was
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detected in normal breast tissues, whereas both CTCF130 and CTCF180
were present in breast tumours [29]. Usually CTCF130 is associated
with cell proliferation, whereas CTCF180 is characteristic for non-pro-
liferating cells of diﬀerent types. The latter include cells from healthy
breast tissues with very low proliferative index [29], cells with induced
cell cycle arrest, DNA damage [29], senescence [30] or apoptosis [28,
29]. Currently all existing information regarding the binding char-
acteristics of CTCF has been mined from the experimental data obtained
for CTCF130, but not CTCF180. It is not known whether the sets of
targets for CTCF130 and CTCF180 are the same, completely diﬀerent or
overlap, and how binding of diﬀerent forms of CTCF may be associated
with alteration in gene expression. One of the reasons for this is that it is
diﬃcult to distinguish between CTCF130 and CTCF180 is the absence
of an antibody speciﬁcally recognizing CTCF180. All existing anti-CTCF
antibodies detect either only CTCF130 or both CTCF130 and CTCF180.
Furthermore, the antibody property diﬀers from batch to batch even for
the same commercial vendor, and in order to select the antibody with
well-deﬁned properties one has to perform screening of several batches,
e.g. using Western blot assays.
In the present study we distinguished between CTCF130 and
CTCF180 binding using a speciﬁc biological system: the immortalized
human luminal breast cell line, 226LDM, which contains mainly non-
PARylated CTCF (CTCF130) in the proliferating cell state, and mainly
highly PARylated CTCF (CTCF180) upon cell cycle arrest with hydro-
xyurea (HU) and nocodazole (NO) [29]. We have previously proved
that the form of CTCF migrating in the gel with the apparent molecular
mass 180 kDa was PARylated (CTCF180) because (i) it could be gen-
erated from the recombinant CTCF by in vitro PARylation, (ii) it im-
munoprecipitated using anti-PAR antibodies and (iii) it contained
peptides speciﬁc for CTCF [27]. Additional data presented below also
conﬁrm that CTCF180 can be detected exclusively in normal primary
breast tissues, whereas both CTCF180 and CTCF130 are present in
MCF7 (cancer) and 226LDM (immortalized) breast cells. Thus, the
226LDM cell model provides us with the unique opportunity to study
both CTCF forms even in the absence of a speciﬁc antibody against
CTCF180. Using this technique we aimed here to analyse the genomic
targets for CTCF130 and CTCF180 in two functional states of 226LDM
cells and connect these to the changes of chromatin states and gene
expression.
2. Materials and methods
2.1. Cell culture
226LDM cells, derived from human luminal breast cells, were pro-
pagated and cell cycle arrested as previously described [29]. In brief,
cells were seeded in ﬂasks and grown in DMEM/F-12 (PAA) supple-
mented with 5 μg/ml insulin, 1 μg/ml hydrocortisone, 20 ng/ml epi-
dermal growth factor, 20 ng/ml cholera toxin (all from Sigma), 10%
fetal bovine serum (FBS) (Biosera), and 50 μg/ml gentamicin (Life
Technologies-Invitrogen) at 37 °C and 5% CO2. To achieve full transi-
tion from CTCF130 to CTCF180 upon cell cycle arrest, the treatment
conditions were further optimised. In particular, 226LDM cells were
exposed to 100mM hydroxyurea for 24 h followed by 1 h of complete
medium, and a further 24 h with 500 ng/ml nocodazole (SIGMA). Cells
in suspension were then harvested and assessed by Western blot assay
to conﬁrm complete transition (i.e. the presence of CTCF180 only and
disappearance of CTCF130). These cells were 79% viable according to
Countess® automated cell counter (Life Sciences, USA) and arrested in
the S- and G2/M-phases [29]. Untreated adherent proliferating
226LDM cells were used as control.
2.2. Immunoblotting
The endogenous protein levels of CTCF were observed by SDS-
PAGE/western blot analysis [31,32] in whole cell lysates of 226LDM
cells from the control and treated populations using a polyclonal anti-
CTCF antibody (Millipore, 07–729, lot # JBC1903613, pre-screened
with the lysates from breast normal and tumour tissues to detect both,
CTCF130 and CTCF180). Anti-tubulin speciﬁc antibody (SIGMA,
T5168) was used as a loading control. Chemiluminescence detection
was performed with the Fusion FX7 gel documentation system (PeqLab)
and the UptiLight (Interchim) reagents according to the manufacturer's
instructions.
2.3. Protein immunoprecipitation (IP)
CTCF IP was performed in 226LDM cells, using anti-CTCF antibody
[33]. 226LDM cells cultured in a T75 ﬂask were trypsinized, washed
twice with PBS and then lysed by vortexing in BF2 (25mM Tris/Hepes -
pH 8.0, 2 mM EDTA, 0.5% Tween20, 0.5 M NaCl, 1:100 Halt protease
inhibitor cocktail). The lysate was incubated on ice for 15min and then
equal volume of BF1 (25mM Tris/Hepes - pH 8.0, 2 mM EDTA, 0.5%
Tween20 and 1:100 Halt protease inhibitor cocktail) was added. For
immunoprecipitation, the cell lysate was pre-cleared by incubating
500 μl of the lysate in 50 μl of pre-blocked Protein A/Sepharose beads
for 30min at 4 °C on a rotor shaker. The sample was then centrifuged at
200×g for 1min at RT and the pre-cleared supernatant was transferred
into a fresh centrifuge tube. 50 μl of the sepharose beads were added to
the pre-cleared lysate along with the anti-CTCF antibody (Millipore, 07-
729, lot # JBC1903613, pre-screened as described in the previous
section) and the samples were incubated overnight at 4 °C on a rotating
wheel. On the following day, the immune-complexes were recovered by
centrifugation at low speed and the supernatant was removed. The
pellet was washed three times with immunoprecipitation buﬀer
(BF1+BF2) and each time the beads were collected with centrifuga-
tion at low speed. The sepharose was then lysed in SDS-lysis buﬀer and
analysed by SDS-PAGE and western blot analysis as described in pre-
vious section.
2.4. ChIP-seq
ChIP was performed using the ZymoSpin kit (Zymo Research) fol-
lowing the manufacturer's instructions. In brief, 5× 106 of 226LDM
cells from the control and the treated populations were cross-linked
with formaldehyde. The crosslinking was quenched with glycine and
the cells were washed twice with PBS with the addition of a protease
inhibitor cocktail before pelleting at 1000 g for 1min at 4 °C. The pellet
was lysed in Chromatin Shearing Buﬀer and sonicated using Bioruptor
Plus (Diagenode) on high power to obtain fragments of 250–300 bp.
ChIP reaction mixes containing sheared chromatin, Chromatin Dilution
Buﬀer, anti-CTCF antibody (Millipore, 07-729, lot # JBC1903613 or
no-antibody for negative control) and protease inhibitor cocktail were
incubated rotating overnight at 4 °C. The next day, ZymoMag Protein A
beads were added to the mix and incubated for 1 h at 4 °C. The com-
plexes were washed with Washing Buﬀers I, II and III and then the
beads were re-suspended in DNA Elution Buﬀer. Following de-cross-
linking with Proteinase K at 65 °C, the ChIP DNA was puriﬁed using the
ZymoSpin IC columns. The samples were stored at −80 °C. The con-
centration of DNA in the ChIP samples was measured using the
NanoDrop 3300 ﬂuorospectrophotometer (Thermo Scientiﬁc) along
with the Quant-iT™ PicoGreen ds DNA assay kit according to the
manufacturer's instructions. Illumina 50-bp paired-end read sequencing
was performed for two biological replicates for each cell state for each
antibody, as well as no-antibody Inputs. The sequencing was performed
using standard Illumina protocols at the University College London
(UCL) Genomics Centre.
2.5. RNA extraction
Total RNA from 226LDM cells (three biological replicates from the
control and three from the treated population) was extracted using the
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TRIsure reagent (Bioline) according to the manufacturer's guidelines.
Brieﬂy, cells grown in a T75 ﬂask were washed twice with PBS, then
scraped oﬀ and pelleted at 300 g for 5min. Following incubation with
TRIsure for 5min at RT, chloroform was added and the sample was
incubated for 15min at RT. After centrifugation at 9500g for 15min at
4 °C, the top aqueous layer was carefully extracted and the genetic
material was precipitated with isopropanol for 20min on ice. After
centrifugation (9.500g/15min/4 °C) the pellet was washed twice in
75% ethanol before air-drying the obtained RNA pellet. The RNA was
solubilized in sterile water (40–50 μl) and heated for 10min at 55 °C.
The pellet was stored at -80 °C. The RNA quality was tested using the
Agilent Bioanalyzer system; the electropherographs are shown in
Supplemental Fig. S2. The library preparation and sequencing using the
Illumina platforms were performed at the University College London
(UCL) Genomics Centre. 50-bp paired-end reads were sequenced for
three biological replicates for each of the two cell states resulting in
20–30 million mapped reads per replicate.
2.6. ChIP-seq analysis
Reads were aligned to the human hg19 genome with the help of
Bowtie [34] allowing only uniquely mapped reads and up to 1 mis-
match, resulting in ~72% of total reads being mapped. Around 25–30
million uniquely mapped reads were obtained from each of two re-
plicate experiments, resulting in 50–60 million reads per condition.
Mapped reads from two replicate experiments were merged together for
each condition before peak calling. Peak calling was performed with
MACS 1.4 [35] with default parameters (P=1e-5), using the corre-
sponding Input (no-antibody control) for each experiment. The inter-
section of genomic intervals were performed using BedTools [36]. Co-
ordinates of CTCF binding sites in MCF-7 determined by the ENCODE
consortium were downloaded from the GEO database (GSM822305).
Promoter coordinates were obtained from the RefSeq database. The
proﬁles of selected regions and genome-wide aggregate proﬁles were
calculated using NucTools [37] and visualised using OriginPro (Origin
Lab) as described previously [37]. Average aggregate occupancy pro-
ﬁles were normalized to 1 at the leftmost end as was done previously
[38]. Sequence motif analysis was performed using HOMER [39].
Precise positioning of CTCF binding sites within each category of CTCF
peaks was done by scanning for the CTCF motif from JASPAR [40]
using RSAT with default parameters [41]. K-means clustering heat
maps were generated using NucTools as described previously [37].
2.7. RNA-seq analysis
Reads were aligned using Novoalign 3.2 to the reference genome
(hg19) and the raw counts were normalized to RPKM values using the
Bam2rpkm tool from Galaxy. Diﬀerential expression was determined
using DeSeq. Genes whose expression change was< 1.5-fold were in-
cluded in the “unchanged” gene expression category. Gene Ontology
(GO) analysis was performed using DAVID [42], Revigo [43], Cytos-
cape [44] and Panther [45]. The list of genes that were associated with
CTCF binding sites in their vicinity (correspondingly, within±
10,000 bp or± 1000 bp from TSS as speciﬁed in the text) was divided
into upregulated/downregulated/no-change based on the RNA-seq
data. When a gene was associated with multiple CTCF sites from dif-
ferent classes, it was counted in each of the corresponding classes. The
lists of upregulated/downregulated/no change genes associated with
CTCF binding sites were intersected with the list of housekeeping genes
from [46] in order to determine the enrichment of housekeeping genes
in each category.
2.8. Data availability
The CTCF and H3K9me3 ChIP-seq as well as RNA-seq data from this
study is deposited to the GEO archive (accession number GSE102237).
3. Results
3.1. 226DM cells treated with hydroxyurea and nocodazole retain
CTCF180 and not CTCF130
The 226LDM cell line was chosen as a model to investigate binding
patterns of CTCF130 and CTCF180 in the genome, because proliferating
226LDM cells predominantly contain CTCF130, whereas after the
treatment with hydroxyurea (HU) and nocodazole (NO) only CTCF180
remains [29]. In addition to our previous work [29], Combined HU/NO
treatment is one of standard procedures for mammalian cell cycle
synchronization: HU treatment alone arrests cells in G1/S phase,
whereas NO-treatment is used to arrest in G2/M phase [7,47]. HU/NO-
treated cells are thus arrested either in G1/S or G2/M; they demonstrate
clear morphological changes becoming rounded and suspended in the
medium [29,30]. In addition to our previous works [29,30], Supple-
mental Fig. S1 (panels A-C) further conﬁrms that CTCF180 can be de-
tected exclusively in normal primary breast tissues, whereas both
CTCF180 and CTCF130 are present in MCF7 (cancer) and 226LDM
(immortalized) breast cells.
Due to batch-to-batch variations speciﬁc screening procedures are
required to select the appropriate antibodies that can recognize both
CTCF130 and CTCF180 [29]. Such tests were conducted in the current
investigation and the antibodies which could recognize both CTCF130
and CTCF180 (Millipore, 07-729, lot # JBC1903613) were selected
from the panel of several anti-CTCF antibodies (unsuccessful antibodies
are not listed). Using these antibodies we established that HU/NO-
treated 226LDM cells lost about 83% of all CTCF signal, and the re-
maining CTCF is entirely in CTCF180 form (Supplemental Fig. S1, pa-
nels D-E). As we have previously showed using HU/NO-treated
226LDM cells the CTCF180 form is unequivocally the PARylated CTCF
form [29]. Our selected antibodies are able to immunoprecipitate both
CTCF forms in untreated 226LDM cells, as shown in Supplemental Fig.
S3. These antibodies were then used for ChIP-seq analysis of CTCF
binding in control (proliferating) and arrested (HU/NO-treated) cells. It
is noted that the selection for the required recognition of both CTCF130
and CTCF180 has decreased the overall antibody eﬃciency in com-
parison with standard antibody batches used previously by us and
others in classical CTCF ChIP-seq (as seen below by the smaller number
of detected CTCF sites and weaker ChIP-seq peak shapes). This is the
compromise which had to be made in order to study the CTCF130/180
switch.
An additional complication of the following analysis is due to a
notable ~83% reduction of the amount of CTCF proteins associated
with the change in the biological states occurred in treated cells
(Supplemental Fig. S1, panel D). Importantly, the CTCF mRNA levels in
treated cells maintained at 59% in comparison with control cells
(Supplemental Table 1). Such moderate variations of CTCF expression
are quite common e.g. during cell diﬀerentiation, and the associated
diﬀerences in CTCF binding between the corresponding cell types are
not dramatic, meaning that a 41% reduction of CTCF expression by
itself would not explain noticeable elimination of DNA-bound CTCF
[13,48]. On the other hand, a reduction of available CTCF would
prioritise CTCF binding to stronger DNA sites over weaker sites. It is
also worth noting that ~83% reduction of the amount of CTCF proteins
does not represent a signiﬁcant technical challenge for ChIP- and ChIP-
Seq experiments and such experiments have been recently successfully
conducted in cell lines even with a close to complete CTCF knockout
[49].
3.2. Analysis of CTCF binding and gene expression proﬁles in proliferating
(control) and arrested (treated) 226LDM cells
The analysis of total transcriptomes of control and treated cells re-
vealed that 2651 genes were diﬀerentially expressed in treated cells
(adjusted P-value < 0.05, log2 fold change> 1.5). Among them 1270
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were up-regulated and 1381 down-regulated. Gene Ontology analysis
performed for ranked genes is shown in Supplemental Figs. S4 and S5.
The changes identiﬁed in the transcriptomes were consistent with the
two biological states of the cells (proliferating vs arrested). Thus, genes
involved in cell cycle arrest, diﬀerentiation and energy reserve meta-
bolic processes were among up-regulated in treated cells, whereas genes
associated with metabolic and cell signaling pathways, ion transport
and cell adhesion were down-regulated. In addition, RNA metabolic
processes were aﬀected in the latter group of genes.
The analysis of CTCF ChIP-seq revealed that the number of detected
CTCF binding sites was considerably higher in control cells (n=9986)
compared to treated cells (n=2271). The reduction of the number of
ChIP-seq peaks in treated cells was consistent with ~83% decrease of
CTCF protein content in the nucleus (Supplemental Fig. S1E) and ~40%
decrease of the ratio of nuclear versus cytoplasmic CTCF content upon
the cell cycle arrest (Supplemental Fig. S6). The intersection of CTCF
binding sites obtained in our experiments with CTCF sites identiﬁed in
breast cancer cells MCF7 by the ENCODE consortium [50], reveals the
overlap of 67% and 19.6% of CTCF sites in control and treated cells,
respectively. The high percentage of the overlap in control 226LDM and
MCF7 cells conﬁrms the speciﬁcity of our ChIP-seq experiment. A lower
percentage of the overlapping CTCF sites in treated 226LDM vs MCF7
reﬂect the speciﬁc eﬀect of CTCF redistribution upon cell treatment.
We have distinguished three groups of CTCF sites with diﬀerent
binding patterns in control and treated cells, which were termed
“common”, “lost” and “gained”. Common sites were bound by CTCF in
both cell states. Lost sites were bound by CTCF in control but not in
treated cells. Gained sites were only observed in treated cells (Fig. 1A).
The majority of sites were lost after treatment, and only 257 common
sites were retained (Fig. 1B).
The enrichment of gene ontology terms of genes with promoters
containing CTCF is shown in the Supplemental Fig. S7. In the common
group, up-regulated genes were enriched in developmental processes
and down-regulated genes were enriched in response to metal ions. In
the lost group, up-regulated genes were enriched in ion binding and
homeostasis processes, whereas most of the down-regulated genes were
associated with signal transduction and adhesion processes. In the
gained group, up-regulated genes were enriched in those involved in
the regulation of macromolecular complexes and membrane transporter
activities, whereas down-regulated genes were enriched in genes in-
volved in nucleotide binding and biosynthetic processes.
Since the number of CTCF sites within promoter regions in the
previous analysis was quite small (e.g. only 35 common CTCF sites at
promoters), at the next step we have extended the area of interest
to± 10,000 bp from transcription start site (TSS). CTCF's action is
known to include the formation of chromatin loops between functional
regions and this distance is well within the typical range of CTCF ac-
tion. Gene Ontology analysis of expression of genes containing CTCF
within±10,000 bp from TSS showed that, collectively for all three
groups, most of these genes were down-regulated upon treatment (1169
or 49.6%); 443 (18.8%) were up-regulated and 744 (31.6%) unchanged
(Fig. 1C, left panel). In comparison with all diﬀerentially expressed
genes, this means that genes associated with CTCF were on average
stronger downregulated (Fisher P-value < 0.00001). When genes
containing CTCF in their vicinity were split according to the status of
that CTCF site (common, lost and gained), a similar pattern emerged:
the majority of CTCF-associated genes (~50–55%) were down-regu-
lated and ~10–20% were up-regulated (Fig. 1C, middle and right pa-
nels). Thus, most CTCF-associated genes lost CTCF and decreased their
expression upon treatment. At the same time, expression did not change
for a large number of genes in these groups (~30–35%). Interestingly, a
large proportion of genes CTCF-associated genes are housekeeping ac-
cording to the classiﬁcation of Eisenberg and Levanon [46]. Unlike the
majority of CTCF-associated genes which where downregulated (Panel
1C), most housekeeping CTCF-associated genes did not change their
expression (Fig. 1D).
Gene ontology analysis of transcriptional changes revealed genes
highly up- or down-regulated in three diﬀerent groups (Fig. 1E). In the
common group, highly up-regulated genes were associated with dif-
ferentiation and down-regulated genes – with cell migration and
apoptosis. In the lost, the largest group, highly up-regulated genes were
enriched in categories associated with anti-apoptotic processes,
whereas most of the highly down-regulated genes were associated with
cell cycle and cell migration processes. In the gained group, both highly
up-regulated and down-regulated genes were enriched in categories
regulating RNA Pol II transcription.
3.3. Relationship between CTCF occupancy and gene expression in control
and treated cells
Next, we investigated the relationship between the changes in CTCF
binding and gene expression. By stratifying all genes containing CTCF
within± 10,000 bp from TSS according to their expression level, we
observed that it was more likely to ﬁnd CTCF in the vicinity of a higher
expressed gene in both control and treated cells (Fig. 2A and B). Fur-
thermore, due to the loss of CTCF near many low-expressed genes upon
treatment, this eﬀect is more pronounced in treated cells (Fig. 2B).
Interestingly, when we stratiﬁed genes by their expression fold change
upon treatment (Fig. 2C), it appeared that there was a clear preference
for retained CTCF at common sites to be associated with genes which
did not change or changed their expression minimally. Genes con-
siderably up- or down-regulated upon treatment have lost CTCF (see the
leftmost and rightmost parts of Fig. 2C).
We also correlated changes in gene expression with the changes in
CTCF occupancies for the three groups of CTCF sites within a more
narrow window±1000 bp from TSS, which is representative for tran-
scription factor binding at promoters [51]. In agreement with ob-
servations above (Fig. 2C), for the group of genes contained common
CTCF sites at their promoters the changes in gene expression were re-
latively small (Fig. 3A), while promoters which lost or gained CTCF
were associated with a much broader range of gene expression levels
(Fig. 3, panels B and C, respectively). No correlation was observed
between CTCF occupancy and gene expression in the common and lost
groups, although small positive correlation (r=0.15) was seen in the
gained group.
3.4. Common and lost, but not gained CTCF sites contain classical CTCF
binding motifs
CTCF employs a combination of its eleven Zinc ﬁngers to bind to
diverse DNA sequences with a consensus ~19 bp motif [52]. Most of
CTCF sites contain the classical consensus sequence, but CTCF sites with
diﬀerent consensus motifs and those which do not match any consensus
motifs have been also reported previously [52–55]. To identify PAR-
ylation speciﬁc features we calculated the nucleotide frequencies as a
function of distance from the summit of CTCF ChIP-seq peak for the
subsets of the sites from the common, lost and gained groups. As shown
in Fig. 4, CTCF sites in the common and lost but not the gained groups
contain classical CTCF recognition motif, enriched with the guanine
and cytosine residues at the summit, although this pattern is more
pronounced for the common sites. Interestingly, the nucleotide dis-
tribution in the 3′ and 5′ ﬂanking regions of the motifs signiﬁcantly
diﬀers between these groups, demonstrating higher GC content in the
common group. This is in line with our previous observation that
common but not lost/gained sites were enriched inside CpG islands for
the system of mouse embryonic stem diﬀerentiation [38].
We have also assessed the strength of CTCF binding for diﬀerent
classes of CTCF sites calculated by the heights of the ChIP-seq peaks
(Fig. 4D). The strongest binding was observed in the control cells in the
common group, which on average almost did not change after treat-
ment. The initial CTCF signal in the lost group was smaller than in the
common sites before treatment, and it signiﬁcantly decreased after
I. Pavlaki et al. BBA - Gene Regulatory Mechanisms 1861 (2018) 718–730
721
D 
E
CTCF sites
9729 lost 2014
gained
B
257 common
0
500
1,000
1,500
2,000
 Unchanged
 Down
 Up
443
(19%)
1169
(50%)
N
um
be
r o
f g
en
es
 w
ith
 C
TC
F
744
(31%)
C
Common Lost Gained
0
500
1000
1500
2000
24 42
197377
919
N
um
be
r o
f g
en
es
 w
ith
 C
TC
F
53
32
591
121
Common Lost Gained
0
10
20
30
40
50
60
G
en
es
 w
ith
 C
TC
F,
 %
0
100
200
300
400
500
245 (47%)
71 (14%)
 Unchanged
 Down
 Up
H
ou
se
ke
ep
in
g 
ge
ne
s 
w
ith
 C
TC
F
204 (39%)
Common Lost Gained
0
50
100
150
200
250
300
350
10
 (5
0%
)
4 
(2
0%
) 63 (47%)
56 (42%)
15
 (1
1%
)
172 (47%)
144 (39%)
50 (14%)6 
(3
0%
)
H
ou
se
ke
ep
in
g 
ge
ne
s 
w
ith
 C
TC
F
Fig. 1. Analysis of CTCF binding and gene expression proﬁles in control and treated 226LDM cells. (A) Schematic illustration of three groups of CTCF sites detected
by ChIP-seq in control and treated cells: common sites are present in both cell states, lost sites are present only in control cells, and gained sites appear only in treated
cells. (B) A pie chart showing the numbers of common, lost and gained CTCF sites. (C) Association of gene expression patterns in control and treated cells with the
three groups of CTCF binding sites present within± 10,000 bp from TSS. Numbers of genes up- regulated, down-regulated and unchanged is shown for all genes near
CTCF according to the above criterium (left). Percentages and numbers of genes with diﬀerent expression patterns for each group of CTCF-binding sites are shown in
the middle and right panels, respectively. (D) Association of gene expression patterns in control and treated cells with the three groups of CTCF binding sites present
within±10,000 bp from TSS of housekeeping genes. Numbers of genes up- regulated, down-regulated and unchanged is shown for all genes near CTCF (left).
Percentages and numbers of genes with diﬀerent expression patterns for each group of CTCF-binding sites are shown in the right panel. (E) Gene ontology terms
enriched for genes containing CTCF within± 10,000 bp from TSS. Genes are ordered by expression fold change. Red colour corresponds to up-regulation, green
colour – down-regulation (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the online version of this paper.)
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treatment. The lowest signal was in the gained group which most likely
reﬂected the nature of CTCF180 binding (very weak or DNA-in-
dependent).
From these analyses we conclude that common and lost sites are
characterised by the presence of the CTCF consensus motif. The stron-
gest CTCF binding is observed for common sites, whereas it is weaker
for the lost sites. Gained sites have no classical CTCF motif and their
CTCF binding is the lowest as expected. Thus, gained sites may re-
present nonspeciﬁc interactions of CTCF with chromatin or regions
where CTCF is indirectly bound to DNA.
3.5. Loss of CTCF binding upon cell treatment is associated with nucleosome
repositioning
The importance of CTCF in the regulation of the nucleosome
distribution has been widely recognized [38]. CTCF binding also often
demarcates distinct chromatin states and protects DNA from methyla-
tion [4,8,56]. Previous studies showed that CTCF regularly positons
several nucleosomes in its vicinity, resulting a characteristic oscillatory
pattern of nucleosome occupancy around CTCF [38,57–59]; this oscil-
latory nucleosome pattern disappears when CTCF binding is lost and
nucleosome depletion at the center of CTCF site is then replaced by a
strongly positioned nucleosome [58]. Thus, it was interesting whether
the CTCF130/180 switch investigated here was associated with some
changes in nucleosome positioning. In our ﬁrst analysis, we considered
the DNA protection from shearing in the no-antibody Input sample as
an indicator of nucleosome occupancy, as was done in several previous
studies [60,61]. It is important to note that while a number of factors
other than nucleosome occupancy can also aﬀect the Input read cov-
erage distribution, the irregularities in the Input coverage landscape
observed at mono-nucleosome scale mostly represent the nucleosome
resistance to the sonication [62]. Essentially, at the mono-nucleosome
scale ChIP-seq Input reads density reﬂects the nucleosome occupancy in
a very similar way as MNase-seq; the diﬀerence from MNase-seq is only
the resolution of nucleosome positioning. Similar to MNase-seq and
many other sequencing techniques, ChIP-seq Input also has sequence-
dependent artifacts of which we are aware [63–65]. In order to increase
the resolution of nucleosome occupancy obtained from ChIP-seq Input
one can plot the density of “plus tags” – the start coordinates of the
reads. Furthermore, the resolution of positions of CTCF binding sites
around which nucleosome positioning is considered can be improved by
substituting CTCF ChIP-seq peaks by exact locations of CTCF sites
within CTCF ChIP-seq peaks found by scanning for the CTCF motif.
Supplementary Fig. S8A shows the average proﬁle of the plus tag
density around CTCF sites within CTCF ChIP-seq peaks lost in treated
cells, deﬁned with single-base pair resolution by CTCF motifs. This
ﬁgure unequivocally shows that the read density reﬂects the nucleo-
some occupancy: in control cells the plus tag density around CTCF sites
shows characteristic oscillations as in standard MNase-seq experiment,
while in treated cells CTCF sites that lost CTCF binding also lost the
nucleosome oscillation pattern. Furthermore, nucleosome depletion at
CTCF site observed in control cells is replaced by a nucleosome occu-
pancy peak in treated cells. The same eﬀect is observed in the total read
density when DNA reads were extended by the average read length,
although in this case the eﬀect is blurred (Supplementary Fig. S8B).
We then performed similar calculations for nucleosome occupancy
around common/lost/gained CTCF peaks without reﬁning CTCF sites to
CTCF motifs. Fig. 5 shows that CTCF130 bound regions in the common
control group are associated with smaller average nucleosome occu-
pancy than the same regions in treated cells. This also correlated with
the reduced strength of CTCF180 binding at these sites after treatment
(Fig. 4D). In the lost group, average nucleosome occupancy increased
after treatment and release of CTCF180 (Fig. 5B), whereas in the gained
group nucleosome occupancy at CTCF180 binding sites did not change
following CTCF recruitment (Fig. 5C). Taken together, these ﬁndings
indicate that CTCF binding and nucleosome occupancy at its binding
site are anti-correlated. This data is consistent with a number of pre-
vious reports on the competition of CTCF with nucleosomes in vivo
[38,59] and with the observation that that the regions including CTCF
site in human cells contain an intrinsic nucleosome positioning signal
for a single nucleosome centered at the CTCT site [66].
Nucleosome redistributions reported in Fig. 5 can be associated with
diﬀerent post-translational histone modiﬁcations. As a test case, we
have performed ChIP-seq using anti-H3K9me3 antibody in untreated
and treated cells. H3K9me3 has been selected because in our previous
work it was shown to be associated with higher density of mapped
reads and higher nucleosome density [58]. As shown in Fig. 6 (panels A
and B), a signiﬁcant H3K9me3 redistribution occurs around common
and lost CTCF sites. Interestingly, no such rearrangements around
gained CTCF sites were observed, which suggests that gained sites may
be non-speciﬁc/non-functional.
Fig. 2. Correlation of CTCF binding within± 10,000 bp from TSS with gene
expression from the corresponding genes. (A) Genes containing CTCF at their
promoters in control cells sorted by expression in control cells. (B) Genes
containing CTCF at their promoters in treated cells sorted by expression in
treated cells. (C) Genes containing CTCF at their promoters in control (black) or
in treated cells (red), sorted by expression fold change between treated and
control cells. Each vertical bar corresponds to one gene. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the online
version of this paper.)
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Since PARylation can change physical CTCF interactions with
chromatin proteins, we have also looked at the chromatin density
proﬁles based on the Input read density near individual CTCF sites (not
at the CTCF binding site itself, but rather in the immediate vicinity).
Examples of speciﬁc gene promoter regions where CTCF-associated
chromatin rearrangements take place following treatment, together
with changes in gene expression patterns, are given in Supplemental
Fig. S9. We noted that in many cases CTCF binding in control cells was
associated with sharp Input peaks in the physical proximity to CTCF,
which disappear in treated cells. In addition, in some cases the Input
and CTCF peaks are situated at diﬀerent ends of the gene (e.g. an Input
peak at the transcription start site (TSS), and CTCF at the transcription
end site (TES) in the case of E2F4 (Supplemental Fig. S9). The latter
suggests possible TSS-TES bridging by CTCF in control cells, which
disappears after treatment. The eﬀect of CTCF-dependent chromatin
reorganization was observed for all three groups of sites (common, lost
and gained), and was not correlated with changes of gene expression
(gene expression could go either up or down following treatment). The
fact that CTCF-dependent chromatin peaks were next to CTCF but did
not coincide with it provides an argument that the chromatin peak is
not formed by CTCF itself. Cell treatment-dependent depletion of Input
peaks near CTCF sites at the PARP3 and TP53 promoters was also
conﬁrmed by ChIP experiments using the DNA primers for the regions
at the summits of the corresponding ChIP-seq Input peaks (panels D and
E in Supplemental Fig. S9). We also analysed proﬁles of H3K9me3
chromatin marks in the same promoters as in Supplemental Fig. S9. As
shown in Supplemental Fig. S10, the strength of H3K9me3 signal in-
creases around the regions near CTCF sites which lost chromatin peaks.
This suggests that perhaps the lost sharp Input peaks represent speciﬁc
chromatin complexes other than nucleosomes.
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4. Discussion
This study aimed to analyse the eﬀect of the CTCF130/180 switch
on chromatin structure and gene expression. In the absence of a speciﬁc
anti-CTCF180 antibody, it was rational to use the 226LDM cell line in
which a switch from CTCF130 to CTCF180 can be induced and vali-
dated using anti-CTCF antibodies recognizing both CTCF130 and
CTCF180. Following the optimization of hydroxyurea and nocodazole
concentrations [30], it was possible to obtain viable treated cells with
CTCF180, whereas CTCF130 was predominantly present in pro-
liferating control cells. Following the cell cycle arrest we observed
~83% decrease of CTCF protein content in the nucleus (Supplemental
Fig. S1E) and ~40% decrease of the ratio of nuclear versus cytoplasmic
CTCF (Supplemental Fig. S6). Such a pattern of CTCF distribution was
previously reported in normal breast tissues where only CTCF180 is
detected. Interestingly, a transition from CTCF180 to CTCF130 took
place in primary cultures generated from normal cells from breast tis-
sues indicating the labile nature of this modiﬁcation [29].
The generation of CTCF180 in response to the drugs can be ex-
plained by the initiation of checkpoint signaling cascades, leading to
activation of PARP enzymes and subsequent PARylation of CTCF.
Indeed, the nocodazole- [67] and hydroxyurea-induced [68] cell cycle
arrests have been linked to the activation of the PARP-signaling path-
ways [69, 70]. Global changes in gene expression proﬁles were con-
sistent with the changes in the biological states of the cells, revealing
up-regulation of genes involved in cell cycle arrest, development,
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diﬀerentiation and energy reserve metabolic processes and down-reg-
ulation of genes associated with metabolic and cell signaling pathways,
ion transport and cell adhesion (Supplemental Figs. S4 and S5).
Our ChIP-seq analysis conﬁrmed for the ﬁrst time that CTCF180 has
well-deﬁned genomics targets, paving the way for further research into
the speciﬁcs of this binding in diﬀerent conditions, cell lines or tissues.
The number of CTCF180 sites detected in treated cells was found to be
much smaller than in control cells (n=2271 vs n=9986, respec-
tively), which is explained by the reduction of the total CTCF con-
centration in chromatin (Supplemental Fig. S6). The remaining smaller
number of common CTCF sites in treated cells may implicate that they
are involved in the organization of 3D chromatin structure, and thus
have higher aﬃnity and are surrounded by other cooperatively inter-
acting proteins. Moreover, the protein composition of CTCF-interacting
complexes is likely to be diﬀerent because of the particular nature of
CTCF180. These aspects will need to be explored in the future,
especially for the primary tissues where CTCF180 is naturally very
abundant (and in some tissues, such as breast, it is the only form).
This study provides new insights in DNA-binding and gene reg-
ulatory properties of CTCF180 summarized in Fig. 7. Our results suggest
that common and lost sites contain the classical CTCF motif, although
the former are more GC-rich at the summit and in the background
around the motif, whereas the latter are embedded into more AT-rich
sequences. A similar eﬀect of common CTCF sites residing in more GC-
rich and CpG-rich areas has been previously noticed in our study of
mouse embryonic stem cell diﬀerentiation [38] and it seems to be a
general eﬀect. The eﬀects of ﬂanking DNA sequences regions may be
also linked to the strength of CTCF binding, which is highest for the
common sites (Fig. 4D). The fact that no CTCF binding motif was ob-
served in the gained group suggests that CTCF-DNA interaction at these
sites is non-speciﬁc or CTCF180 interacts with these regions in a DNA-
independent manner, directly or through recruitment by other proteins.
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The change in nucleosome occupancy resulting from loss of CTCF
observed here is similar to the eﬀect of CTCF/nucleosome competition
that was previously reported [48,71,72] and it could be one of the
mechanisms explaining CTCF redistribution. Additional mechanisms
can be through treatment-induced changes of chromatin modiﬁcations.
At least one of histone modiﬁcations redistributing at common and lost
(but not gained) CTCF binding sites was found to be a heterochromatin
mark H3K9me3. The latter is in agreement with down-regulation of the
majority of the genes within these regions (Fig. 1). On the other hand,
many up-regulated genes were also associated with CTCF, implying the
involvement of additional regulatory factors/mechanisms [49,71,73].
The complexity of this regulation is further illustrated by the
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observations that changes of CTCF binding at promoters were asso-
ciated with chromatin rearrangements in the regions adjacent to CTCF
binding sites (Supplemental Figs. S9 and S10). It did not escape our
attention that chromatin rearrangement in the vicinity of PARylated
CTCF sites may represent a general eﬀect, but exploring its nature
would require additional extensive experiments which are beyond the
scope of the current work. Interestingly, the connection of chromatin
PARylation to its decompaction has been noted recently, which might
be related to the eﬀect reported here [74]. However, one should be also
cautious to not over-interpret individual ChIP-seq Input peaks due to
possible artifacts [60,75–77].
The majority of CTCF-associated genes experienced both CTCF loss
and gene expression downregulation (Fig. 1). Unchanged expression of
a signiﬁcant number of genes that lost and gained CTCF near their TSS
indicates that the regulation of some genes does not depend on CTCF
binding. This eﬀect is particularly pronounced the case for the common
group in which it may be important to sustain the optimal level of
expression needed for survival of cells in diﬀerent functional states
(Figs. 1D and 3).
The importance of CTCF modiﬁcation in the biological processes is
supported by changes in expression proﬁles of genes associated with
CTCF (Figs. 1E and 7, far right). These changes involve down-regulation
if genes involved in cell cycle and cell migration, and up-regulation of
genes involved in diﬀerentiation thereby adequately reﬂecting the
biological situation, i.e. transition from proliferating to arrested cells.
Furthermore, some of the aﬀected genes appear to be characteristic for
particular groups of CTCF sites. For example, genes responsible for cell
cycle regulation are down-regulated in the group of genes where CTCF
is lost. It is tempting to speculate that such preference may be due to the
change of behaviour of PARylated CTCF at the particular type of CTCF
sites.
It should be noted that in this report we investigate local eﬀects of
CTCF PARylation on its DNA binding properties and, subsequently,
changes in adjacent chromatin regions and associated gene expression.
It was beyond our scope to consider in this experimental model 3D
eﬀects of CTCF rearrangements on higher order chromatin structures
[12,49,71,73,78–80], which may be a subject of the follow up work.
Interestingly, the eﬀect of CTCF PARylation observed in treated
cells was not a direct consequence of increased expression of PARP
genes. Indeed, PARP-family genes were either downregulated upon
treatment (PARP1: fold-change 0.3, adjusted P=0.01; PARP16: fold-
change 0.3, adjusted P=0.02) or did not change their expression sig-
niﬁcantly (PARP2, PARP3, PARP4, PARP6, PARP8, PARP9, PARP10,
PARP11, PARP12, PARP14, PARP15). This is consistent with PARP1
downregulation in G1 arrested cells reported recently [81]. In addition,
enzyme PARG that is responsible for de-PARylation was only insignif-
icantly downregulated in treated cells (fold change 0.45, adjusted
P=0.38). Therefore, one can speculate that the change of CTCF
PARylation is due to changed stability or activity of (de)PARylation
enzymes rather than their expression levels. In addition, the lack of
PARP1 upregulation suggests that the DNA damage response pathways
are not among the major determinants of CTCF relocation. Note also
that the promoter of one of the main DNA damage response players,
p53, is one of the few genes marked by the common CTCF sites.
The eﬀect of CTCF PARylation studied here may be also considered
in the general context of posttranslational CTCF modiﬁcations (similar
to the language of histone modiﬁcations), which may deserve a new
systematic study due to the particular importance of CTCF in cell
functioning. For example, another CTCF modiﬁcation, phosphorylation,
is abundant during mitosis, and has been also reported to aﬀect CTCF
binding aﬃnity to chromatin [82]. CTCF is believed to be retained
during mitosis at some but not all sites [83–85], an important subject
related to our system, which is still not entirely understood. Further-
more, mitotic bookmarking in general is an active area of research [86].
Another example posing an unresolved puzzle is the apparent dis-
appearance of CTCF during S phase reported for mouse embryonic stem
cells [87], which may be explained by some CTCF post-translational
modiﬁcation that makes it un-detectable with standard antibodies. Our
results may help elucidate some of the controversies in the ﬁeld, which
at least in part may be attributed to CTCF changes that make them
“invisible” to some antibodies.
Finally, this study issues an important cautionary note concerning
the design and interpretation of any experiments using cells and tissues
where CTCF180 may be present and can go undetected since not all
antibodies can recognize this form of CTCF. The 226LDM cells as a
model for the switch from CTCF130 to CTCF180 provided us with a
unique opportunity to develop an experimental framework to study
CTCF180. This approach can be used to investigate the role of CTCF180
in cell lines and tissues, normal and tumour, where either both forms or
exclusively CTCF180 are present. The screening of the existing anti-
bodies for their ability to recognize either both forms of CTCF or
CTCF130 only will be necessary to enable to subtract the targets re-
cognized by CTCF130 from the combined CTCF130/CTCF180.
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